Brii, RemeGen, CanSino, I-Mab win top company honors at BayHelix awards

Brii Biosciences capped a big year for the company that included a $320 million IPO with the receipt of the R&D Achievement of the Year award at the 2021 BayHelix Awards on Wednesday.

Led by Zhi Hong,  Brii Biosciences Ltd. (HKEX:2137) raised HK$2.5 billion in a July IPO on the Hong Kong stock exchange that sets the company up to advance at least a dozen programs in the clinic in the U.S. and China. Of these, the company’s BRII-196/BRII-198 mAb combination to treat COVID-19 landed the company the award, which recognizes a scientific discovery in China with direct impact to drug R&D. The therapy is under review for emergency use authorization by FDA...